These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23046320)

  • 41. Evaluation of the Biodegradable Igaki-Tamai Scaffold After Drug-Eluting Balloon Treatment of De Novo Superficial Femoral Artery Lesions: The GAIA-DEB Study.
    Werner M; Schmidt A; Scheinert S; Banning-Eichenseer U; Ulrich M; Bausback Y; Steiner S; Scheinert D
    J Endovasc Ther; 2016 Feb; 23(1):92-7. PubMed ID: 26620399
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Amputation-free Survival in Patients with Critical Limb Ischemia Treated with Paclitaxel-eluting Stents and Paclitaxel-coated Balloons.
    Phair J; Carnevale M; Lipsitz EC; Shariff S; Scher L; Garg K
    Ann Vasc Surg; 2020 Jan; 62():8-14. PubMed ID: 31207400
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
    Tepe G; Schroeder H; Albrecht T; Reimer P; Diehm N; Baeriswyl JL; Brechtel K; Speck U; Zeller T
    J Endovasc Ther; 2020 Apr; 27(2):276-286. PubMed ID: 32096451
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical outcome of drug-coated balloon angioplasty in patients with femoropopliteal disease: A real-world single-center experience.
    AbuRahma AF; AbuRahma ZT; Scott G; Adams E; Beasley M; Davis M; Dean LS; Davis E
    J Vasc Surg; 2019 Dec; 70(6):1950-1959. PubMed ID: 31401115
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
    Tran K; Ullery BW; Kret MR; Lee JT
    Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry.
    Micari A; Cioppa A; Vadalà G; Castriota F; Liso A; Marchese A; Grattoni C; Pantaleo P; Cremonesi A; Rubino P; Biamino G
    JACC Cardiovasc Interv; 2012 Mar; 5(3):331-8. PubMed ID: 22440500
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain: 2-Year Results From the IN.PACT Global Study.
    Micari A; Brodmann M; Keirse K; Peeters P; Tepe G; Frost M; Wang H; Zeller T;
    JACC Cardiovasc Interv; 2018 May; 11(10):945-953. PubMed ID: 29798770
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 2-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
    Micari A; Nerla R; Vadalà G; Castriota F; Grattoni C; Liso A; Russo P; Pantaleo P; Roscitano G; Cremonesi A
    JACC Cardiovasc Interv; 2017 Apr; 10(7):728-734. PubMed ID: 28385412
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis.
    Mori S; Hirano K; Nakano M; Muramatsu T; Tsukahara R; Ito Y; Ishimori H
    J Endovasc Ther; 2015 Jun; 22(3):341-9. PubMed ID: 25862363
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study.
    Tepe G; Zeller T; Schnorr B; Claussen CD; Beschorner U; Brechtel K; Scheller B; Speck U
    J Endovasc Ther; 2013 Dec; 20(6):792-800. PubMed ID: 24325695
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Local Ultrasound to Enhance Paclitaxel Delivery After Femoral-Popliteal Treatment in Critical Limb Ischemia: The PACUS Trial.
    Gandini R; Del Giudice C
    JACC Cardiovasc Interv; 2016 Oct; 9(20):2147-2153. PubMed ID: 27765310
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease.
    Müller-Hülsbeck S; Keirse K; Zeller T; Schroë H; Diaz-Cartelle J
    J Endovasc Ther; 2016 Oct; 23(5):701-7. PubMed ID: 27193308
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A new paclitaxel-eluting balloon for angioplasty of femoropopliteal obstructions: acute and midterm results.
    Micari A; Cioppa A; Vadalà G; Stabile E; Castriota F; Pantaleo P; Grattoni C; Cremonesi A; Marchese A; Rubino P; Biamino G
    EuroIntervention; 2011 May; 7 Suppl K():K77-82. PubMed ID: 22027734
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon: One-year single centre clinical results.
    Cioppa A; Stabile E; Popusoi G; Salemme L; Cota L; Pucciarelli A; Ambrosini V; Sorropago G; Tesorio T; Agresta A; Biamino G; Rubino P
    Cardiovasc Revasc Med; 2012; 13(4):219-23. PubMed ID: 22632996
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.
    Caradu C; Lakhlifi E; Colacchio EC; Midy D; Bérard X; Poirier M; Ducasse E
    J Vasc Surg; 2019 Sep; 70(3):981-995.e10. PubMed ID: 31126769
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paclitaxel-Coated Balloon for the Treatment of Infrainguinal Disease: 12-Month Outcomes in the All-Comers Cohort of BIOLUX P-III Global Registry.
    Tepe G; Zeller T; Moscovic M; Corpataux JM; Christensen JK; Keirse K; Nano G; Schroeder H; Binkert CA; Brodmann M
    J Endovasc Ther; 2020 Apr; 27(2):304-315. PubMed ID: 31989855
    [No Abstract]   [Full Text] [Related]  

  • 57. Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The Chronic Total Occlusion Cohort in the IN.PACT Global Study.
    Tepe G; Micari A; Keirse K; Zeller T; Scheinert D; Li P; Schmahl R; Jaff MR;
    JACC Cardiovasc Interv; 2019 Mar; 12(5):484-493. PubMed ID: 30846089
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease.
    Bosiers M; Scheinert D; Peeters P; Torsello G; Zeller T; Deloose K; Schmidt A; Tessarek J; Vinck E; Schwartz LB
    J Vasc Surg; 2012 Feb; 55(2):390-8. PubMed ID: 22169682
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Short-term Results of the RAPID Randomized Trial of the Legflow Paclitaxel-Eluting Balloon With Supera Stenting vs Supera Stenting Alone for the Treatment of Intermediate and Long Superficial Femoral Artery Lesions.
    de Boer SW; van den Heuvel DAF; de Vries-Werson DAB; Vos JA; Fioole B; Vroegindeweij D; Elgersma OE; Tutein Nolthenius RP; Heyligers JMM; Bosma GPT; de Leeuw B; Bouwman LH; Böckler D; Dovzhanskiy DI; Vos FWF; Vink TWF; Hooijboer PGA; Hissink RJ; de Vries JPM
    J Endovasc Ther; 2017 Dec; 24(6):783-792. PubMed ID: 28795638
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease: evidence from a multicenter registry.
    Micari A; Cioppa A; Vadalà G; Castriota F; Liso A; Marchese A; Grattoni C; Pantaleo P; Cremonesi A; Rubino P; Biamino G
    JACC Cardiovasc Interv; 2013 Mar; 6(3):282-9. PubMed ID: 23517840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.